Snapshot from Jul 07, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Uganda / Mapp Biopharmaceutical

Uganda & Mapp Biopharmaceutical

2 shared events · Importance 4 · Last updated Jul 04, 2026

Importance
4
Shared Events
2
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
Shared Events (2)
42
Tech
WHO Lists Bundibugyo Ebola Test
Uganda: Uganda has reported cases of the Bundibugyo ebolavirus outbreak, linked to cross-border transmission from the Democratic Republic of the Congo. The new diagnostic test will aid Uganda's response efforts, although no new cases have been reported there since June 21.
Mapp Biopharmaceutical: Mapp Biopharmaceutical's experimental MBP134 antibody is being evaluated in a treatment trial for the Bundibugyo Ebola outbreak in the Democratic Republic of the Congo, either as a standalone treatment or in combination with Gilead Sciences' remdesivir.
Jul 02, 2026 · 8 articles
35
Tech
Ebola Treatment Trial Begins DRC
Uganda: Uganda has confirmed cases linked to the Ebola outbreak in the Democratic Republic of the Congo, highlighting the risk of cross-border transmission.
Mapp Biopharmaceutical: Mapp Biopharmaceutical developed MBP134, an experimental monoclonal antibody treatment being tested in the Ebola clinical trial. The United States government has funded research for this drug.
Apr 20, 2026 · 67 articles
NEWSDESK
Explore this relationship live

Track how Uganda and Mapp Biopharmaceutical interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.